Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 8,037 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Not applicable Interventional

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

NCT00001008
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

NCT00074425
View directory record Official record
Conditions
HIV Infections
Interventions
BufferGel, PRO 2000/5 Gel, Placebo gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 30, 2026, 6:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

NCT04790240
View directory record Official record
Conditions
Covid19 Virus Infection
Interventions
Inflammation (I), Inflammation (II), Inflammation (III), Standard of care
Dietary Supplement · Drug
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 1 Interventional

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

NCT04419623
View directory record Official record
Conditions
COVID-19, Sars-CoV2, Cancer, Solid Tumor, Carcinoma, Blood Cancer
Interventions
TL-895
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Augusta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 30, 2026, 6:59 PM EDT
Not listed Phase 1 Interventional

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

NCT03588715
View directory record Official record
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 30, 2026, 6:59 PM EDT
Not listed Phase 3 Interventional

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

NCT04935476
View directory record Official record
Conditions
COVID-19
Interventions
Dapsone 85 mg PO BID, Placebo 85 mg PO BID
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
40 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

CSP #512 - Options in Management With Anti-Retrovirals

NCT00050089
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART
Other · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
29
States / cities
Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 30, 2026, 6:59 PM EDT
Not listed No phase listed Observational

Gazelle COVID-19 Test Clinical Accuracy Protocol

NCT04987918
View directory record Official record
Conditions
Covid19
Interventions
Applied Biosystems TaqPath COVID- 19 Combo Kit
Diagnostic Test
Lead sponsor
Hemex Health
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bellingham, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00978497
View directory record Official record
Conditions
HCV Infection
Interventions
placebo, ANA598, Peginterferon, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • San Clemente, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 30, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

NCT00614458
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir; valproic acid
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Oct 30, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

NCT01459913
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

NCT00002213
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:59 PM EDT
Completed No phase listed Observational

Hepatitis C Screening Alerts

NCT05710120
View directory record Official record
Conditions
Hepatitis C
Interventions
Hepatitis C Screening Alerts in CHORUS™, Standard of Care
Other
Lead sponsor
Epividian
Industry
Eligibility
18 Years and older
Enrollment
125,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Not applicable Interventional

Psychoeducation for Hepatitis and Alcohol Behaviors

NCT00598416
View directory record Official record
Conditions
Hepatitis C, Substance Abuse
Interventions
Family-Responsive Psychoeducation Program (PERF)
Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 30, 2026, 6:59 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine

NCT00109304
View directory record Official record
Conditions
Venezuelan Equine Encephalitis
Interventions
VEE 3526
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

NCT00001038
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

NCT02532764
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
QR-010, Placebo
Drug
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project UNITY - HIV Risk Reduction and Vaccine Education Interventions

NCT00150098
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Enhanced HIV risk reduction and HIV vaccine education
Behavioral
Lead sponsor
New York Blood Center
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

NCT00802347
View directory record Official record
Conditions
Delayed Graft Function, Other Complication of Kidney Transplant
Interventions
I5NP, Saline
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

NCT00344305
View directory record Official record
Conditions
Healthy
Interventions
Trivalent influenza virus vaccine live, intranasal
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 59 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
16
States / cities
Little Rock, Arkansas • Marietta, Georgia • Bardstown, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

NCT02307851
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent VLP Vaccine, Comparator TIV
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection

NCT01097395
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
ribavirin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 30, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Glutathione and Function in HIV Patients

NCT02348775
View directory record Official record
Conditions
HIV Infection, Erythrocyte Glutathione Deficiency
Interventions
GlyNAC (combination of glycine and n-acetylcysteine)
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 6:59 PM EDT
Recruiting No phase listed Observational

Expanding HOPE Liver

NCT07778459
View directory record Official record
Conditions
HIV Infection, Liver Transplant
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 6:59 PM EDT